Main navigation

KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PVMF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (KRT-232-101)